Media Inquiries

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]
Sort by Year
November 4, 2021

Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update

November 4, 2021

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

October 25, 2021

More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021

October 21, 2021

Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call

September 2, 2021

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

August 26, 2021

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label

August 5, 2021

Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance

August 3, 2021

Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer

July 22, 2021

Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call

June 16, 2021

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

June 7, 2021

Ironwood Pharmaceuticals Announces Leadership Updates

May 26, 2021

Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength

May 24, 2021

More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)

May 17, 2021

Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021

May 6, 2021

Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

Copyright © 2021, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.